Lupus Nephritis (LN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lupus Nephritis (LN) Market Outlook

Thelansis’s “Lupus Nephritis (LN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lupus Nephritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lupus Nephritis (LN) Overview

Lupus nephritis (LN) is a severe complication in patients with systemic lupus erythematosus (SLE). Its prevalence varies depending on factors such as ethnicity, sex, and age of disease onset, ranging from 35% to 60%. LN, along with increased susceptibility to infections, significantly contributes to the morbidity and mortality of SLE patients. Histologically observed in most SLE patients (even those without apparent renal symptoms), renal involvement is characterized by hypertension, proteinuria, and eventual renal failure. Lupus nephritis is classified into six classes based on kidney biopsy findings: minimal mesangial lupus nephritis (class I), mesangial proliferative lupus nephritis (class II), focal lupus nephritis (class III), diffuse lupus nephritis (class IV), membranous lupus nephritis (class V), and advanced sclerosing lupus nephritis (class VI). The pathogenesis of LN is complex. It involves abnormalities in various immune system components, including B and T cells, the complement cascade, cytokines, and clearance of apoptotic cells. The diagnosis of LN is suspected based on changes in laboratory parameters, such as elevated creatinine levels, the presence of hematuria and proteinuria, and low serum complement levels. Treatment approaches for LN commonly involve a combination therapy of corticosteroids with either cyclophosphamide or mycophenolate. Once remission is achieved, maintenance therapy consists of gradually reducing the corticosteroid dosage and using an antimetabolite. The differential diagnosis for LN includes other causes of nephrotic syndrome, nephrolithiasis, hydronephrosis, medication-induced acute kidney injury, and acute interstitial nephritis. The long-term prognosis of LN varies depending on the class of nephritis. Classes I (minimal) and II (proliferative mesangial) generally have a favorable prognosis, while prognosis worsens as the disease progresses through different classes. Class III has a poor prognosis, and class IV is associated with the poorest prognosis. The timing of therapy initiation also affects prognosis, with earlier treatment initiation leading to better disease outcomes.

• The estimated annual prevalence of lupus nephritis in the USA is approximately 21.2 cases per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: